Results 71 to 80 of about 35,534 (303)

Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma

Frontiers in Genetics, 2019
As a transcription factor, MYCN regulates myriad target genes including the histone chaperone FACT. Moreover, FACT and MYCN expression form a forward feedback loop in neuroblastoma.
Xinjie Hu, Weisheng Zheng, Qianshu Zhu, Liang Gu, Yanhua Du, Zhe Han, Xiaobai Zhang, Daniel R. Carter, Daniel R. Carter, Daniel R. Carter, Belamy B. Cheung, Belamy B. Cheung, Andong Qiu, Andong Qiu, Cizhong Jiang, Cizhong Jiang   +15 more
doaj   +1 more source

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

Cancer Research, 2021
Effective treatment of pediatric solid tumors has been hampered by the predominance of currently “undruggable” driver transcription factors. Improving outcomes while decreasing the toxicity of treatment necessitates the development of novel agents that ...
Adam J. Wolpaw, R. Bayliss, G. Büchel, C. Dang, M. Eilers, W. Gustafson, Gwenn H. Hansen, N. Jura, S. Knapp, M. Lemmon, D. Levens, J. Maris, R. Marmorstein, S. Metallo, Julie R. Park, L. Penn, M. Rapé, M. Roussel, K. Shokat, W. Tansey, K. Verba, S. Vos, W. Weiss, E. Wolf, Y. Mossé   +24 more
semanticscholar   +1 more source

MYCN-targeting vaccines and immunotherapeutics [PDF]

Human Vaccines & Immunotherapeutics, 2016
Amplification and concomitant overexpression of the MYCN oncogene is a frequent event in many malignancies including the childhood tumors, neuroblastoma and medulloblastoma. MYCN is only expressed in a defined time frame during early developmental processes, (1) which is beneficial for approaches combatting tumor-specific MYCN.
Schramm, Alexander, Lode, Holger
openaire   +3 more sources

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]

, 2017
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht, Claeys, Shana, De Preter, Katleen, Denecker, Geertrui, Durinck, Kaat, Kumps, Candy, Speleman, Franki   +6 more
core   +3 more sources

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma

Journal of experimental & clinical cancer research : CR, 2022
Background Neuroblastoma is a deadly childhood cancer, and MYCN -amplified neuroblastoma (MNA-NB) patients have the worst prognoses and are therapy-resistant.
S. Lampis, Salvatore Raieli, L. Montemurro, Damiano Bartolucci, Camilla Amadesi, Sonia Bortolotti, Silvia Angelucci, A. Scardovi, Giammario Nieddu, Lucia Cerisoli, F. Paganelli, S. Valente, M. Fischer, A. Martelli, G. Pasquinelli, A. Pession, P. Hrelia, R. Tonelli   +17 more
semanticscholar   +1 more source

Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma

Cancers, 2022
Simple Summary MYCN gene amplification, the strongest prognostic marker of aggressive neuroblastoma, is detected on invasive biopsy tissues. This study aimed to establish a less invasive method to detect MYCN status based on MYCN mRNA contents in large ...
Jirawan Panachan, Napat Rojsirikulchai, N. Pongsakul, Ladawan Khowawisetsut, Pongpak Pongphitcha, T. Siriboonpiputtana, T. Chareonsirisuthigul, Pitichai Phornsarayuth, Nisakorn Klinkulab, N. Jinawath, Wararat Chiangjong, U. Anurathapan, K. Pattanapanyasat, S. Hongeng, S. Chutipongtanate   +14 more
semanticscholar   +1 more source

RETRACTED: Targeting MYCN IRES in MYCN‐amplified neuroblastoma with miR‐375 inhibits tumor growth and sensitizes tumor cells to radiation

Molecular Oncology, 2015
The MYCN oncogene is amplified in 20% of neuroblastomas, leading to its overexpression at both the mRNA and protein levels. MYCN overexpression is strongly associated with advanced disease stage, rapid tumor progression and a worse prognosis.
Hailong Zhang, Tao Liu, Sha Yi, Lubing Gu, Muxiang Zhou   +4 more
doaj   +1 more source

Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter [PDF]

, 1967
Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects.
Brunak, Søren, Halasz, Melinda, Huber, Kilian V.M., Kolch, Walter, Papamarkou, Theodore, Radic-Sarikas, Branka, Superti-Furga, Giulio, Tsafou, Kalliopi P., Winter, Georg E.   +8 more
core   +3 more sources

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma

Cell Stress, 2022
Ferroptosis is an iron-dependent, oxidative form of cell death that is countered mainly by glutathione peroxidase 4 (GPX4) and the production of glutathione (GSH), which is formed from cysteine.
K. Floros, Ayesha T. Chawla, Mia O. Johnson-Berro, Rishabh Khatri, Angeliki M. Stamatouli, S. Boikos, M. Dozmorov, L. A. Cowart, A. Faber   +8 more
semanticscholar   +1 more source

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas. [PDF]

PLoS Genetics, 2014
The rearrangement of pre-existing genes has long been thought of as the major mode of new gene generation. Recently, de novo gene birth from non-genic DNA was found to be an alternative mechanism to generate novel protein-coding genes.
Yusuke Suenaga, S M Rafiqul Islam, Jennifer Alagu, Yoshiki Kaneko, Mamoru Kato, Yukichi Tanaka, Hidetada Kawana, Shamim Hossain, Daisuke Matsumoto, Mami Yamamoto, Wataru Shoji, Makiko Itami, Tatsuhiro Shibata, Yohko Nakamura, Miki Ohira, Seiki Haraguchi, Atsushi Takatori, Akira Nakagawara   +17 more
doaj   +1 more source